TGen, Scottsdale Healthcare study shows Abraxane/gemcitabine combination extends survival of pancreatic cancer patients
A multi-center Phase III clinical trial demonstrates that Abraxane (nab-paclitaxel) plus gemcitabine extends survival of... (Source: TGen News)
Source: TGen News - January 22, 2013 Category: Genetics & Stem Cells Authors: TGEN Tags: Science News Source Type: news
TGen, Scottsdale Healthcare study shows drug combination extends pancreatic cancer patient survival
(The Translational Genomics Research Institute) A multi-center Phase III clinical trial demonstrates that Abraxane (nab-paclitaxel) plus gemcitabine is the first combination of cancer drugs to extend survival of late-stage pancreatic cancer patients compared to standard treatment. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - January 22, 2013 Category: Biology Source Type: news
